RAD Neurim Pharmaceuticals

Neurim Pharmaceuticals is a drug discovery and development company focused on the central nervous system, specifically in the fields of sleep medicine and neurodegeneration. The company is widely recognized for developing Circadin, the first approved prolonged-release melatonin treatment for insomnia in older adults. Neurim's portfolio also includes Slenyto, a pediatric formulation of melatonin for children with neurodevelopmental disorders. Beyond sleep, the company is investigating novel compounds for the treatment of Alzheimer's disease and other age-related conditions. Headquartered in Israel and part of the RAD Group, Neurim maintains a global presence through strategic licensing and distribution partnerships.